Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

Inclusion Criteria: * Who are able and willing to give signed informed consent * Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator. * Who have up to 20% of body surface area (BSA) afflicted with plaques * Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study. Exclusion Criteria: * Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity. * Who are pregnant or lactating. * Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease. * Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests. * Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study. * Whose serum calcium levels exceed the upper limit of reference range * Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of treatment. * Who have been treated with systemic therapy within 30days of treatment. * Who have treated with biologics within 5 half-lives of the biologics before the day of treatment * Who have been treated with topical therapy within 14days before the day of treatment.